The historical rank and industry rank for Diplomat Pharmacy's EV-to-EBIT or its related term are showing as below:
DPLO's EV-to-EBIT is not ranked *
in the Drug Manufacturers industry.
Industry Median: 17.115 * Ranked among companies with meaningful EV-to-EBIT only.
The historical data trend for Diplomat Pharmacy's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Diplomat Pharmacy's EV-to-EBIT
For the Drug Manufacturers - Specialty & Generic subindustry, Diplomat Pharmacy's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Diplomat Pharmacy's EV-to-EBIT Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Diplomat Pharmacy's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Diplomat Pharmacy's EV-to-EBIT falls into.
Diplomat Pharmacy's current Enterprise Value is $304 Mil.
Diplomat Pharmacy's EBIT for the trailing twelve months (TTM) ended in Sep. 2019 adds up the quarterly data reported by the company within the most recent 12 months, which was $-613 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Diplomat Pharmacy's Enterprise Value for the quarter that ended in Sep. 2019 was $940 Mil.
Diplomat Pharmacy's EBIT for the trailing twelve months (TTM) ended in Sep. 2019 adds up the quarterly data reported by the company within the most recent 12 months, which was $-613 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Diplomat Pharmacy EV-to-EBIT Related Terms
Thank you for viewing the detailed overview of Diplomat Pharmacy's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.
Diplomat Pharmacy (Diplomat Pharmacy) Business Description
Diplomat Pharmacy Inc. is active in the U.S. healthcare sector. It provides specialty pharmacy and infusion services, including pharmacy solutions for chronic diseases. The company has two main segments: specialty pharmacy and pharmacy benefit management. Its specialty pharmacy segment offers solutions to dispense, deliver, and dose prescription drugs. The pharmacy benefit management segment offers services to help control pharmacy benefit dollars and maximize quality of care. It derives most of its revenue through prescription drug sales in the United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
DPLO has been successfully added to your 